Use of incretin-based therapies.

27 August 2018 (11:22 - 11:45)

Organised by:

Video

Sign in for access options

Slides

About the speaker

Professor Lars Ryden

Karolinska Institute, Stockholm (Sweden)

3 More presentations in this session

Presentation thumbnail

Epigenetic signatures and cardiovascular risk in diabetes.

Professor F. Cosentino (Stockholm, SE)

Presentation thumbnail

Mechanisms of cardiovascular impact of SGLT2 inhibitors.

Professor B. Staels (Lille Cedex, FR)

Presentation thumbnail

SGLT2 inhibitors and alteration of substrate metabolism.

Professor E. Ferrannini (Pisa, IT)

Access the full session

Session thumbnail

How do SGLT2 inhibitors and incretin-based therapy exert their effects on cardiovascular disease?

The Event

ESC Congress 2018

27 August 2018 11:22 CET

You may be interested in

Congress Session

Guidelines in Practice: 2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes

27 August 2023

Congress Presentation

Empagliflozin use versus dipeptidyl peptidase 4 inhibitors reduces risk of cardiovascular and renal disease among type 2 diabetes patients in routine care in europe and israel: EMPRISE study results

29 June 2021

Congress Presentation

Glucagon like peptide-1 receptor agonists and their combination with sodium-glucose cotransporter-2 inhibitors improve myocardial deformation and work index in type-2 diabetes after 12-month treatment

28 August 2020

Congress Presentation

GLP1-RA versus metformin as first-line therapy for achieving glycemic control and risk-factor management - a one-year nationwide cohort study

28 August 2023

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources